Patients with mild to moderate atopic dermatitis (AD) historically have had a narrow range of treatment options available to them, including corticosteroids that are not recommended for long-term use. The development of Janus kinase (JAK) inhibitors shows promise for treating patients with refractory AD. In this article, Brett King, MD, PhD, discusses the development of topical and oral JAK inhibitors, the role they can play in treating patients with refractory mild to moderate AD, and what may be yielded from future research on these drugs.
Special Collections
